TOP2? Overexpression And Its Association With Clinicopathological Features And Prognosis In Gastric Cancer After R0 Resection

Purpose: Published studies showed that topoisomerase II alpha(TOP2?)expression influenced the clinicopathological features and prognosis among some tumors.However,few studies reported the associations between TOP2? expression and clinicopathological features and prognosis in gastric cancer(GC).The objectives of study were to investigate the relationship between TOP2? overexpression and clinicopathological features and prognosis.Method: All selected GC patients were formalin fixed and paraffin embedded tumor tissues.Then,we conducted a retrospective study on 1232 patients of four hospitals from December 2009 to December 2011,and all the patients received telephone follow-up or in/out-patient review.Finally,we analyzed the clinicopathological features and prognosis in GC with TOP2? expression.And we further estimated the relationship between TOP2? expression and postoperative chemotherapy in GC patients.Results: In this study,TOP2? overexpression correlated with location of tumor(P < 0.001),depth of invasion(P = 0.002),and pTNM stage(P = 0.002).However,TOP2? overexpression have on association with other clinicopathological features,including gender(P = 0.199),age(P = 0.459),tumor differentiation(P = 0.071),nodal invasion(P = 0.192),lymphatic and blood vessel invasion(P = 0.382),and nervous infiltration(P = 0.382).Moreover,TOP2? overexpression was associated with lower 5-year overall survival(OS)in non-cardia GC patients younger than 60 years old(P = 0.023).Multivariate analysis demonstrated TOP2? overexpression was an independent prognostic factor for these patients.Moreover,univariate analysis and multivariate analyses showed TOP2? overexpression associated with worse 5-year OS in non-cardia GC patients younger than 60 years old and receiving postoperative chemotherapy(P = 0.048).Conclusions: This study demonstrated that TOP2? overexpression played a crucial role in clinicopathological features in these GC patients.And TOP2?overexpression was a predictor of 5-year OS in non-cardia GC patients younger than60 years old and non-cardia GC patients younger than 60 years old receiving postoperative chemotherapy.